

Amendments To The Claims

1-6. (Withdrawn).

7. (Currently amended) A method for treating a subject having B-cell lymphoma, which subject is refractory to treatment with a non-radiolabeled has not exhibited appreciable tumor remission or regression after administration of a chimeric anti-CD20 antibody, comprising administering to said patient a radiolabeled anti-CD20 antibody.

8. (Original) The method of Claim 7, wherein said radiolabeled anti-CD20 antibody is administered from about one week to about two years after said administration of said chimeric anti-CD20 antibody.

9. (Original) The method of Claim 8, wherein said radiolabeled anti-CD20 antibody is administered from about one week to about nine months after said administration of said chimeric anti-CD20 antibody.

10-31. (Withdrawn).

32. (New) The method of claim 7, wherein the non-radiolabeled chimeric anti-CD20 antibody is rituximab.

33. (New) The method of claim 7, wherein the radiolabeled anti-CD20 antibody is a murine anti-CD20 antibody.

34. (New) The method of claim 33, wherein the radiolabeled murine anti-CD20 antibody is 2B8.

35. (New) The method of claim 7, wherein the radiolabeled anti-CD20 antibody is a ⁹⁰Y-labeled anti-CD20 antibody.

36. (New) The method of claim 7, wherein the radiolabeled anti-CD20 antibody is a ^{131}I -labeled anti-CD20 antibody.

37. (New) The method of claim 7, further comprising administering a B cell depleting amount of a non-radiolabeled chimeric anti-CD20 antibody to the subject prior to administration of the radiolabeled anti-CD20 antibody.